Published on
Nov 18, 2024
Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment ...
Designations underscore significant unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists. Data from Alkeus’ TEASE program were presented at the American Academy of Ophthalmology’s 2024 annual meeting. Alkeus …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
